ERBB2 and non-small cell lung carcinoma: In the DESTINY-Lung01 trial, T-DXd was investigated in recurrent/refractory HER2 IHC 2/3+ overexpressing (cohort 1) and HER2 mutant (cohort 2) NSCLC.